Vertical transmission of maternal COVID-19 antibodies after CoronaVac vaccine: A case report

Menegali, Bruno Thizon; Schuelter‐Trevisol, Fabiana; Barbosa, Alexandre Naime; Izidoro, Talita Menegali; Feurschuette, Otto Henrique May; Marcon, Chaiana Esmeraldino Mendes; Trevisol, Daisson José

doi:10.1590/0037-8682-0385-2021

Cited by 6 publications

(5 citation statements)

References 11 publications

(18 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Nevertheless, data on the interval of schedules to maximize the passive immunity in newborns and type of vaccines are currently very limited. Only a few studies have been published, including BNT-162b2 (Pfizer-BioNTech) and mRNA-1273 (Moderna) vaccines [ 12 , 13 , 16 ] and a case report of inactivated virus antigen (CoronaVac ® ) [ 17 ]. The antibody levels were much higher in mothers who had received two doses of an mRNA vaccine than those who received only one dose [ 18 , 19 ].…”

Section: Discussionmentioning

confidence: 99%

Placental Transfer Immunity to the Newborns in a Twin Pregnant Women Vaccinated with Heterologous CoronaVac-ChAdOx1

et al. 2023

View full text Add to dashboard Cite

Pregnant women who receive the COVID-19 vaccine develop anti-SARS-CoV-2 antibodies, which can be transferred to the fetus. However, the effectiveness of placental transfer has not been evaluated in twin pregnancy, especially in cases vaccinated with heterologous CoronaVac (Sinovac)—ChAdOx1 (Oxford-AstraZeneca) regimen, which was commonly used in many countries. Case: A 34-year-old Thai woman with a twin pregnancy attended our antenatal care clinic at 21 + 2 weeks of gestation and requested COVID-19 vaccination. Her medical history and physical examination were unremarkable. She had not received COVID-19 vaccination before. Ultrasound screening for fetal anomaly revealed a dichorion diamnion twin pregnancy. Both twins showed no structural anomaly. She received the CoronaVac vaccine at 21 + 2 weeks of gestation without serious side effects and the ChAdOx1 vaccine at 24 + 2 weeks of gestation. Cesarean delivery was performed at 36 + 5 weeks of gestation, giving birth to the two healthy babies. The levels of anti-spike protein IgG levels (BAU/mL) in maternal blood just before delivery and umbilical cord blood of the two newborns were 313.349, 678.219, and 874.853, respectively. The levels of % inhibition (wild-type and delta) in the two newborns were also higher than those in the mother. In conclusion, heterologous CoronaVac-ChAdOx1-S vaccination in a twin pregnancy could effectively provide protective immunity to both twin newborns. The antibody levels in both were approximately two times higher than those in the mothers. This case report may serve as a reference in counseling couples with a twin pregnancy, while the studies on placental transfer of vaccine-derived antibodies in twin pregnancy are currently not available, especially in countries experiencing a vaccine shortage or unavailability of mRNA vaccines.

show abstract

Section: Discussionmentioning

confidence: 99%

Placental Transfer Immunity to the Newborns in a Twin Pregnant Women Vaccinated with Heterologous CoronaVac-ChAdOx1

et al. 2023

View full text Add to dashboard Cite

show abstract

“…Overall, the literature presents that vaccination is not associated with a higher risk of pregnancy difficulties and, for the time being, is a safe practice for pregnant women. Even with emerging variants of concern of the SARS-CoV-2 virus, such as Delta or Omicron, and their associated increased adverse maternal and fetal outcomes, vaccination has proven to be reducing severe maternal complications [95][96][97].…”

Section: Covid-19 Vaccination Timing In Pregnant Womenmentioning

confidence: 99%

Implications of COVID-19 Pandemic on Pregnancy: Current Status and Controversies

Greenberg,

Vishwakarma,

Tirupattur

et al. 2023

COVID

View full text Add to dashboard Cite

The COVID-19 pandemic unnerved the global population in 2019 and has continued to evolve ever since. Throughout this time, investigations concerning the health of the groups most susceptible to this virus, including the elderly, those with compromised immunity or chronic diseases, and pregnant women, have taken place. Numerous articles have been formulated on the effects of COVID-19 infection on maternal, fetal, and neonatal health, but there are many controversies that still exist within the current literature. Even three years later, it is not fully understood how a maternal infection or vaccination of COVID-19 can impact pregnancy and the fetus, and these topics require further investigation and conclusive results. The aim of this article is to explain the risks for a mother and the neonate, during and after pregnancy, with the emergence of the COVID-19 pandemic. Additionally, this report presents the current state of the literature on whether vaccination during pregnancy is more beneficial or harmful. Finally, this review examines studies regarding the exacerbation of the effects of COVID-19 on pregnancies in various organ systems, particularly the cardiovascular system, in relevance to pre-existing and emerging conditions and the ethnicity of the mother.

show abstract

“…Apesar dos riscos elevados no que tange ao uso de remédios em relação ao binômio materno-fetal, um estudo estadunidense de mais de 3000 gestantes não identificou padrões de desfechos adversos nessas pacientes 27 . No estudo de Menegali e colaboradores 28 , sugere-se a imunização passiva fetal por via transplacentária após a vacinação da gestante no terceiro trimestre, o que demanda investigações adicionais de riscos e benefícios.…”

Section: D1 Da Astrazenecaunclassified

Eventos adversos pós-vacinais em pacientes imunizados contra a COVID-19 em um município do sul de Santa Catarina no ano de 2021

Silva,

Margotti,

Marcon

2023

Medicina (Ribeirão Preto)

View full text Add to dashboard Cite

A disponibilização em massa de vacinas contra o vírus SARS-CoV-2 é resultado de esforços científicos mundiais. Entretanto, a insegurança e a hesitação popular per-meiam os movimentos antivacinais. Objetivo: Analisar o perfil dos Eventos Adver-sos Pós-Vacinais (EAPV) na cidade de Tubarão-SC no ano de 2021. Metodologia: Estudo epidemiológico transversal com dados de todas as fichas de notificação padrão de EAPV no município de Tubarão em 2021. As variáveis analisadas foram o perfil epidemiológico do paciente, imunobiológico administrado, o tipo de evento e a evolução do caso. Calculou-se a taxa de incidência (TI) para 10 mil doses apli-cadas. Resultados: A população em estudo foi de 274 pacientes, sendo 73% do sexo feminino, com média das idades de 39,8±14,5 anos. Foram aplicadas 197.001 doses no ano de 2021, o que resultou em uma TI geral de EAPV de 13,9. Houve 206 reações notificadas em pacientes imunizados com a AstraZeneca (TI=29,1), 43 com a Pfizer (TI=5,1), 18 com a Coronavac (TI=4,8) e sete com a Janssen (TI=13,8). Houve apenas sete casos classificados como graves (TI=0,3) e, destes, um paciente evoluiu com óbito, sem relação causal estabelecida. Conclusão: A incidência geral de eventos graves foi baixa, o que corrobora o perfil de segurança dos imunobiológicos disponíveis contra a COVID-19.

show abstract

Vertical transmission of maternal COVID-19 antibodies after CoronaVac vaccine: A case report

Cited by 6 publications

References 11 publications

Placental Transfer Immunity to the Newborns in a Twin Pregnant Women Vaccinated with Heterologous CoronaVac-ChAdOx1

Placental Transfer Immunity to the Newborns in a Twin Pregnant Women Vaccinated with Heterologous CoronaVac-ChAdOx1

Implications of COVID-19 Pandemic on Pregnancy: Current Status and Controversies

Eventos adversos pós-vacinais em pacientes imunizados contra a COVID-19 em um município do sul de Santa Catarina no ano de 2021

Contact Info

Product

Resources

About